Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1207-2816 | Other Identifier | World Health Organization (WHO) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes (T2DM) patients across five selected countries in Europe. Participants will be asked to give information about their health. Participants will continue their normal way of life and will not get any medication other than what has been prescribed to them by their doctor. Participants' participation will be one day/one visit at study doctor. The study will last for about 3 months in total.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| T2DM patients seen in routine practice | All anti-diabetic and cardiovascular (CV) medication will be prescribed at the physician's discretion under routine clinical practice conditions. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No treatment given | Other | No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions. |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnosed with cerebrovascular disease: Ischaemic stroke, haemorrhagic stroke, stroke (unspecified) and/or transient ischaemic attack | Percentage of participants (Y/N). | Day 1 |
| Diagnosed with CVD: Myocardial infarction, stable coronary artery disease (SCAD) also referred as angina (pectoris), other ischaemic heart disease and/or past revascularisation procedures | Percentage of participants (Y/N). | Day 1 |
| Diagnosed with symptomatic heart failure: New York Heart Association Functional Classification (NYHA) (group IIIV) and/or left ventricular ejection fraction (LVEF) greater than or equal to 50 percent, LVEF 40-49 percent and LVEF less than 40 percent) | Percentage of participants (Y/N). | Day 1 |
| Diagnosed with asymptomatic heart failure | Percentage of participants (Y/N). | Day 1 |
| Hospitalisation for heart failure | Percentage of participants (Y/N). | Day 1 |
| Diagnosed with cardiac arrhythmia: Atrial fibrillation or flutter, ventricular tachycardia and/or ventricular fibrillation | Percentage of participants (Y/N). | Day 1 |
| Diagnosed with aortic diseases: Aortic dissection, aortic aneurysms and/or thromboembolic aortic disease | Percentage of participants (Y/N). |
| Measure | Description | Time Frame |
|---|---|---|
| High risk of CVD (above 20% over 10 years) according to the risk engine from the United Kingdom Prospective Diabetes Study (UKPDS) | Percentage of participants (Y/N). | Day 1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study population will consist of male and female adults diagnosed with (type 2 diabetes mellitus (T2DM).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Reporting Anchor and Disclosure (1452) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novo Nordisk Investigational Site | Benátky nad Jizerou | 29471 | Czechia | |||
| Novo Nordisk Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34315481 | Result | Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, Dieuzeide G, Eriksen KT, Hong T, Kaltoft MS, Lengyel C, Rhee NA, Russo GT, Shirabe S, Urbancova K, Vencio S; CAPTURE Study Investigators. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021 Jul 27;20(1):154. doi: 10.1186/s12933-021-01344-0. | |
| 35012646 |
Not provided
Not provided
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 1 |
| Diagnosed with peripheral artery disease: Asymptomatic peripheral arterial disease (PAD) defined as Low Ankle-Brachial Index (less than 0.90) or pulse abolition, claudication, limb ischemia and/or non-traumatic amputation | Percentage of participants (Y/N). | Day 1 |
| Diagnosed with carotid artery disease | Percentage of participants (Y/N). | Day 1 |
| Boskovice |
| 68001 |
| Czechia |
| Novo Nordisk Investigational Site | Brandýs nad Labem | 25001 | Czechia |
| Novo Nordisk Investigational Site | Břeclav | 69002 | Czechia |
| Novo Nordisk Investigational Site | Chomutov | 43004 | Czechia |
| Novo Nordisk Investigational Site | Hradec Králové | 50341 | Czechia |
| Novo Nordisk Investigational Site | Kroměříž | 76701 | Czechia |
| Novo Nordisk Investigational Site | Olomouc | 77900 | Czechia |
| Novo Nordisk Investigational Site | Orlová | 73514 | Czechia |
| Novo Nordisk Investigational Site | Ostrava | 70200 | Czechia |
| Novo Nordisk Investigational Site | Ostrava | 71800 | Czechia |
| Novo Nordisk Investigational Site | Pilsen | 30100 | Czechia |
| Novo Nordisk Investigational Site | Prague | 14000 | Czechia |
| Novo Nordisk Investigational Site | Chartres | 28000 | France |
| Novo Nordisk Investigational Site | Courpière | 63120 | France |
| Novo Nordisk Investigational Site | Le Creusot | 71200 | France |
| Novo Nordisk Investigational Site | Lyon | 69007 | France |
| Novo Nordisk Investigational Site | Montélimar | 26200 | France |
| Novo Nordisk Investigational Site | Saint-Saëns | 76680 | France |
| Novo Nordisk Investigational Site | Sathonay-Camp | 69580 | France |
| Novo Nordisk Investigational Site | Strasbourg | 67000 | France |
| Novo Nordisk Investigational Site | Tarare | 69170 | France |
| Novo Nordisk Investigational Site | Vénissieux | 69200 | France |
| Novo Nordisk Investigational Site | Albano Laziale | 00041 | Italy |
| Novo Nordisk Investigational Site | Ariano Irpino | 83031 | Italy |
| Novo Nordisk Investigational Site | Bagno a Ripoli | 50012 | Italy |
| Novo Nordisk Investigational Site | Brindisi | 72100 | Italy |
| Novo Nordisk Investigational Site | Catanzaro | 88100 | Italy |
| Novo Nordisk Investigational Site | Fano | 61032 | Italy |
| Novo Nordisk Investigational Site | Ferrara | 44123 | Italy |
| Novo Nordisk Investigational Site | Florence | 50134 | Italy |
| Novo Nordisk Investigational Site | Messina | 98128 | Italy |
| Novo Nordisk Investigational Site | Milan | 20162 | Italy |
| Novo Nordisk Investigational Site | Naples | 80121 | Italy |
| Novo Nordisk Investigational Site | Negrar (VR) | 37024 | Italy |
| Novo Nordisk Investigational Site | Orvieto | 05018 | Italy |
| Novo Nordisk Investigational Site | Partinico (PA) | 90047 | Italy |
| Novo Nordisk Investigational Site | Ravenna | 48121 | Italy |
| Novo Nordisk Investigational Site | Roma | 00161 | Italy |
| Novo Nordisk Investigational Site | Rozzano (MI) | 20089 | Italy |
| Novo Nordisk Investigational Site | Savigliano (CN) | 12038 | Italy |
| Derived |
| Vencio S, Vianna AGD, da Silva MACF, Precoma DB. Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study. Diabetol Metab Syndr. 2022 Jan 10;14(1):5. doi: 10.1186/s13098-021-00775-9. |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided